Literature DB >> 20532545

Progression in ALS is not linear but is curvilinear.

Paul H Gordon1, Bin Cheng, Francois Salachas, Pierre-Francois Pradat, Gaelle Bruneteau, Philippe Corcia, Lucette Lacomblez, Vincent Meininger.   

Abstract

The aim of the study is to determine the shape of the progression curve in ALS, assess the impact of clinical variables on the rate of progression, and evaluate the association between functional decline and survival. Data were prospectively collected and entered into a clinical database from all patients seen in 2002-2008 at the Centre SLA, Hôpital de la Salpêtrière, Paris. Variables analyzed were demographic and baseline information, the ALS functional rating scale (ALSFRS-R), strength testing (MMT), and survival. Generalized additive mixed models characterized changes in ALSFRS-R and MMT scores over time. Linear mixed effects assessed the impact of demographic and clinical measures on rate of progression and Cox models examined their effect on survival. Of 2,452 patients with ALS identified, 1,884 had adequate data for analysis. The ALSFRS-R and MMT declined in a curvilinear way; a quadratic fit described the trends but a linear fit did not. The total ALSFRS-R score was negatively associated with age-of-onset (p < 0.001), and positively associated with baseline ALSFRS-R (p < 0.001) as well as more severe bulbar features (p < 0.001). Higher rate of decline in ALSFRS-R and MMT, older age-at-onset and bulbar-onset predicted shorter survival. Deterioration in ALS is non-linear. The early and late phases of the illness show the most rapid rates of decline. Older age and bulbar signs are associated with a steeper decline, and along with more rapid initial rate of decline, but not current functional status, also predict survival.

Entities:  

Mesh:

Year:  2010        PMID: 20532545     DOI: 10.1007/s00415-010-5609-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  The rate of decline in function in Alzheimer's disease and other dementias.

Authors:  A B Mitnitski; J E Graham; A J Mogilner; K Rockwood
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1999-02       Impact factor: 6.053

Review 3.  Natural history of amyotrophic lateral sclerosis. A discussion.

Authors:  V Meininger; G Bensimon; L Lacomblez; F Salachas
Journal:  Adv Neurol       Date:  1995

4.  Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.

Authors:  B G Jenkins; P Klivenyi; E Kustermann; O A Andreassen; R J Ferrante; B R Rosen; M F Beal
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

5.  The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials.

Authors:  J Pradas; L Finison; P L Andres; B Thornell; D Hollander; T L Munsat
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.

Authors:  Paulo Guimaraes; Karl Kieburtz; Christopher G Goetz; Jordan J Elm; Yuko Y Palesch; Peng Huang; Bernard Ravina; Caroline M Tanner; Barbara C Tilley
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

7.  Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note.

Authors:  J K Milliken; S D Edland
Journal:  Stat Med       Date:  2000 Jun 15-30       Impact factor: 2.373

8.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

9.  Cognitive decline in Alzheimer disease: Impact of spirituality, religiosity, and QOL.

Authors:  Yakir Kaufman; David Anaki; Malcolm Binns; Morris Freedman
Journal:  Neurology       Date:  2007-05-01       Impact factor: 9.910

10.  Defining survival as an outcome measure in amyotrophic lateral sclerosis.

Authors:  Paul H Gordon; Philippe Corcia; Lucette Lacomblez; Ksenia Pochigaeva; Jean-Louis Abitbol; Merit Cudkowicz; P Nigel Leigh; Vincent Meininger
Journal:  Arch Neurol       Date:  2009-06
View more
  42 in total

Review 1.  Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival.

Authors:  John D Beard; Freya Kamel
Journal:  Epidemiol Rev       Date:  2014-10-31       Impact factor: 6.222

2.  Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study.

Authors:  Christina Schuster; Elisabeth Kasper; Judith Machts; Daniel Bittner; Jörn Kaufmann; Reiner Benecke; Stefan Teipel; Stefan Vielhaber; Johannes Prudlo
Journal:  J Neurol       Date:  2013-08-31       Impact factor: 4.849

Review 3.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 4.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

5.  Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering.

Authors:  Ming Tang; Chao Gao; Stephen A Goutman; Alexandr Kalinin; Bhramar Mukherjee; Yuanfang Guan; Ivo D Dinov
Journal:  Neuroinformatics       Date:  2019-07

6.  Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.

Authors:  Daichi Yokoi; Naoki Atsuta; Hazuki Watanabe; Ryoichi Nakamura; Akihiro Hirakawa; Mizuki Ito; Hirohisa Watanabe; Masahisa Katsuno; Yuishin Izumi; Mitsuya Morita; Akira Taniguchi; Masaya Oda; Koji Abe; Kouichi Mizoguchi; Osamu Kano; Satoshi Kuwabara; Ryuji Kaji; Gen Sobue
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

7.  Speech network regional involvement in bulbar ALS: a multimodal structural MRI study.

Authors:  Sanjana Shellikeri; Matthew Myers; Sandra E Black; Agessandro Abrahao; Lorne Zinman; Yana Yunusova
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-05-14       Impact factor: 4.092

Review 8.  The neuropathological signature of bulbar-onset ALS: A systematic review.

Authors:  S Shellikeri; V Karthikeyan; R Martino; S E Black; L Zinman; J Keith; Y Yunusova
Journal:  Neurosci Biobehav Rev       Date:  2017-02-02       Impact factor: 8.989

9.  Outcome measures in amyotrophic lateral sclerosis clinical trials.

Authors:  Sabrina Paganoni; Merit Cudkowicz; James D Berry
Journal:  Clin Investig (Lond)       Date:  2014

10.  Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Smriti Agarwal; Elizabeth Highton-Williamson; Jashelle Caga; José M Matamala; Thanuja Dharmadasa; James Howells; Margaret C Zoing; Kazumoto Shibuya; Nimeshan Geevasinga; Steve Vucic; John R Hodges; Rebekah M Ahmed; Matthew C Kiernan
Journal:  J Neurol       Date:  2018-06-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.